0RD1 Stock Overview A biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Camurus AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for Camurus Historical stock prices Current Share Price SEK 596.00 52 Week High SEK 714.00 52 Week Low SEK 418.60 Beta 1.0 1 Month Change 5.21% 3 Month Change -2.30% 1 Year Change 14.16% 3 Year Change 363.45% 5 Year Change 496.30% Change since IPO 804.31%
Recent News & Updates
Camurus AB (Publ) Revises Earnings Guidance for the Year 2024 Jan 24
Camurus AB (publ), Annual General Meeting, May 27, 2025 Nov 12
Third quarter 2024 earnings released: EPS: kr2.21 (vs kr1.56 in 3Q 2023) Nov 08 Camurus AB (publ) to Report Q1, 2025 Results on May 15, 2025
Camurus Provides Regulatory Update on the US NDA for CAM2029 in Acromegaly Oct 22
President recently sold kr39m worth of stock Sep 22 See more updates
Camurus AB (Publ) Revises Earnings Guidance for the Year 2024 Jan 24
Camurus AB (publ), Annual General Meeting, May 27, 2025 Nov 12
Third quarter 2024 earnings released: EPS: kr2.21 (vs kr1.56 in 3Q 2023) Nov 08 Camurus AB (publ) to Report Q1, 2025 Results on May 15, 2025
Camurus Provides Regulatory Update on the US NDA for CAM2029 in Acromegaly Oct 22
President recently sold kr39m worth of stock Sep 22
New minor risk - Insider selling Jul 19
Chief Technology Officer recently sold kr6.8m worth of stock Jul 19
Second quarter 2024 earnings released: EPS: kr1.28 (vs kr5.44 in 2Q 2023) Jul 17
Camurus Announces Positive Phase 3 Results from the Acroinnova 2 Study of Octreotide Sc Depot (Cam2029) in Acromegaly Patients Jul 15
Camurus Announces the Publication in JAMA Network Open of A New Post H Holes Analysis from A 24-Week Randomized, Double-Blind, Phase 3 Study Jun 26
Camurus Receives EMA Acceptance of MAA Filing for Octreotide SC Depot (Cam2029) for the Treatment of Acromegaly May 25
Chief Technology Officer recently sold kr845k worth of stock May 16
First quarter 2024 earnings released: EPS: kr1.36 (vs kr1.06 in 1Q 2023) May 09
Camurus AB (Publ) Announces Board Resignations Apr 02
Full year 2023 earnings released: EPS: kr7.78 (vs kr1.01 in FY 2022) Mar 31
Camurus AB (Publ) Announces FDA Acceptance of NDA Submission for Oclaiz™ for Treatment of Acromegaly Mar 05
Full year 2023 earnings released: EPS: kr7.78 (vs kr1.01 in FY 2022) Feb 16
Investor sentiment deteriorates as stock falls 17% Feb 15
Camurus AB Provides Earnings Guidance for the Full Year 2024 Feb 15
Camurus AB Appoints Behshad Sheldon as President of Camurus Inc. and Member of the it's Executive Management Team, Starting 1 April 2024 Feb 13
Camurus AB (Publ) Completes Enrollment in the POSITANO Study of CAM2029 in Patients with Polycystic Liver Disease Feb 08
Investor sentiment deteriorates as stock falls 15% Jan 19
New minor risk - Shareholder dilution Jan 18 Camurus AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.09 billion.
Camurus AB (publ) Submits New Drug Application to the US FDA for Oclaiz for Treatment of Acromegaly Dec 21
Camurus AB Announces Completed Enrollment in the Phase 3 SORENTO Study of CAM2029 in Patients with Neuroendocrine Tumors Dec 14 Camurus AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024
Third quarter 2023 earnings released: EPS: kr1.56 (vs kr0.63 in 3Q 2022) Nov 10
Camurus AB (Publ) Raises Earnings Guidance for the Year 2023 Oct 24 Camurus AB (publ), Annual General Meeting, May 08, 2024
Insider recently sold kr295k worth of stock Sep 22
Camurus Announces US Launch of Brixadi for the Treatment of Moderate to Severe Opioid Use Disorder by Braeburn Sep 07
Camurus AB (Publ) Provides Earnings Outlook for the Year 2023 Jul 21
New major risk - Earnings quality Jul 20
Second quarter 2023 earnings released: EPS: kr5.44 (vs kr0.15 in 2Q 2022) Jul 19
Camurus Announces New Phase 3 Data Recalling Long-Term Safety and Efficacy of Octreotide Sc Depot (Cam2029) in Patients with Acromegaly Jul 17
Camurus Announces Positive Topline Results from A 24-Week Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, Acromegaly Jun 20
President recently sold kr23m worth of stock May 28
Camurus Announces FDA Approval of Brixadi for the Treatment of Moderate to Severe Opioid Use Disorder May 24
First quarter 2023 earnings released: EPS: kr1.06 (vs kr0.014 loss in 1Q 2022) May 11 Camurus AB (Publ) Elects Erika Söderberg Johnsson as Board Member
Full year 2022 earnings released: EPS: kr1.01 (vs kr1.66 loss in FY 2021) Feb 14 Camurus AB (Publ) Provides Earnings Guidance for the Year 2023
Camurus Announces PDUFA Date for Brixadi NDA for the Treatment of Opioid Use Disorder in the US Dec 10
Camurus AB (Publ) Provides Earnings Guidance for the Year 2022 Nov 10
Camurus AB (publ), Annual General Meeting, May 10, 2023 Oct 19 Camurus AB (publ) to Report Fiscal Year 2022 Final Results on Mar 30, 2023
Second quarter 2022 earnings released: EPS: kr0.15 (vs kr0.89 loss in 2Q 2021) Jul 16
Camurus AB (Publ) Raises Operating Result Guidance for the Full Year 2022 Jul 15
Solasia Pharma K.K. (TSE : 4597) acquired Episil oral liquid business from Camurus AB (publ) (OM : CAMX). Jul 09
First quarter 2022 earnings released: kr0.01 loss per share (vs kr0.40 loss in 1Q 2021) May 13 Camurus AB (Publ) Elects Stefan Persson as New Board Member
Full year 2021 earnings released: kr1.66 loss per share (vs kr3.18 loss in FY 2020) Apr 09
Camurus AB (Publ) Provides Earnings Guidance for the Fiscal Year 2022 Apr 07
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 17
Camurus AB (Publ) Provides Earnings Guidance for the Fiscal Year 2022 Feb 16
Camurus Announces Dosing Initiated in Phase 3 Trial of Weekly Setmelanotide in Pants with Genetic Obesity Disoisorder Jan 14
Forecast breakeven date pushed back to 2022 Dec 31
Camurus AB Announces Braeburn Receives New Complete Response Letter for Brixadi in the US Dec 16
Insider recently sold kr392k worth of stock Dec 04
The European Medicines Agency Accepts Camurus's Application to Extend the Buvidal Indication to Include Treatment of Chronic Pain Nov 30
Independent Chairman recently bought kr852k worth of stock Nov 17
Third quarter 2021 earnings released: kr0.11 loss per share (vs kr0.38 loss in 3Q 2020) Nov 05
Forecast to breakeven in 2021 Sep 23
Camurus AB (Publ) Announces FDA Grants Orphan Drug Designation in the US for CAM2029 for the Treatment of Polycystic Liver Disease Sep 19
Independent Director recently bought kr79k worth of stock Jul 28
Second quarter 2021 earnings released: kr0.89 loss per share (vs kr0.39 loss in 2Q 2020) Jul 16
Camurus AB (Publ) Provides Earnings Guidance for the Year 2021 Jul 15
Camurus AB Announces Braeburn Resubmits New Drug Application for Brixadi in the US Jun 16
Insider recently sold kr1.9m worth of stock May 26
Camurus Announces Publication Superior Patient Treatment Satisfaction with Buvidal® Weekly and Monthly Depot Injections in Opioid Dependence May 12
First quarter 2021 earnings released: kr0.40 loss per share (vs kr1.19 loss in 1Q 2020) May 08
Camurus Re-Affirms Financial Outlook for 2021 May 07
The Australian TGA Approves Key Label Updates to Camurus AB (publ)'s Buvidal® for Treatment of Opioid Dependence May 05
Full year 2020 earnings released: kr3.18 loss per share (vs kr6.23 loss in FY 2019) Apr 18
New 90-day high: kr220 Feb 20
Full year 2020 earnings released: kr3.12 loss per share (vs kr6.23 loss in FY 2019) Feb 12 Shareholder Returns 0RD1 GB Pharmaceuticals GB Market 7D 5.2% 1.7% 1.6% 1Y 14.2% 1.5% 10.2%
See full shareholder returns
Return vs Market: 0RD1 exceeded the UK Market which returned 10.2% over the past year.
Price Volatility Is 0RD1's price volatile compared to industry and market? 0RD1 volatility 0RD1 Average Weekly Movement 4.5% Pharmaceuticals Industry Average Movement 6.6% Market Average Movement 4.9% 10% most volatile stocks in GB Market 11.3% 10% least volatile stocks in GB Market 2.7%
Stable Share Price: 0RD1 has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0RD1's weekly volatility (4%) has been stable over the past year.
About the Company Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud’s phenomenon.
Show more Camurus AB (publ) Fundamentals Summary How do Camurus's earnings and revenue compare to its market cap? 0RD1 fundamental statistics Market cap SEK 35.17b Earnings (TTM ) SEK 266.21m Revenue (TTM ) SEK 1.69b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0RD1 income statement (TTM ) Revenue SEK 1.69b Cost of Revenue SEK 128.76m Gross Profit SEK 1.56b Other Expenses SEK 1.29b Earnings SEK 266.21m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
Earnings per share (EPS) 4.53 Gross Margin 92.38% Net Profit Margin 15.76% Debt/Equity Ratio 0%
How did 0RD1 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/24 11:29 End of Day Share Price 2025/01/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Camurus AB (publ) is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Oscar Haffen Lamm Bryan Garnier & Co Alexandru Cogut Bryan Garnier & Co Kristofer Liljeberg-Svensson Carnegie Investment Bank AB
Show 7 more analysts 
